Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly allograft (R3 Stem Cell)
- Development stage
- Unknown
- Lead developer
- R3 Stem Cell
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
Wharton's jelly allograft is a regenerative biologic therapy developed by R3 Stem Cell for the treatment of chronic low back pain. Derived from the umbilical cord, Wharton's jelly is a gelatinous tissue rich in mesenchymal stem cells (MSCs), growth factors, cytokines, exosomes, and hyaluronic acid. The therapy is designed to be injected into the lumbar region to provide structural support, cushioning, and lubrication to damaged spinal tissues while potentially facilitating a regenerative environment to reduce pain and improve function. R3 Stem Cell is currently evaluating the safety and feasibility of a 10cc injection of this allograft in a Phase 1 pilot study (NCT06361485) for participants with chronic lumbar pain. The product is positioned as an FDA 361-compliant tissue product for homologous use.
- Brand names
- ReBellaWJ
- Other names
- Umbilical Cord Wharton's Jelly AllograftWJ allograftWharton's Jelly
Beyond the preview
Go deeper on Wharton's jelly allograft (R3 Stem Cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly allograft (R3 Stem Cell).